• SU5416: From VEGFR2 Blockade to PAH Models

  2026-08-17

  SU5416, also known as Semaxanib, is more than a cancer research angiogenesis inhibitor: it is a valuable tool for interpreting how VEGFR2 blockade reshapes vascular biology. This article connects its mechanism with proteomic biomarker research in pulmonary arterial hypertension while clarifying model-specific assay and dosing decisions.

• Mithramycin A: Mechanism and Research Workflow

  2026-08-17

  Mithramycin A is an anticancer antibiotic that binds G-C-rich DNA in the presence of divalent metal ions and can suppress transcriptional programs such as c-myc. This article defines its molecular rationale, evidence boundaries, and practical workflow for leukemia research and cancer biology research.

• Dacomitinib in Cancer Research: Workflow Guide

  2026-08-16

  Build a practical Dacomitinib workflow for linking irreversible ErbB signaling blockade with apoptosis, cell-cycle, and mitochondrial stress assays. The guide also shows how PF-00299804 can be used as a mechanistic perturbation in HER2-amplified breast cancer research, EGFR-driven lung models, and exploratory ferroptosis studies.

• E-4031 for 3D Cardiac Electrophysiology

  2026-08-15

  E-4031 provides a precise pharmacological challenge for hERG-dependent repolarization studies, including 3D organoid assays that go beyond conventional planar recordings. Paired with shell microelectrode arrays and calcium imaging, it helps connect QT interval prolongation-like electrical changes with spatial conduction and arrhythmogenic behavior.

• AO/PI Double Staining Kit for Cell Fate Profiling

  2026-08-14

  The AO/PI Double Staining Kit provides a rapid fluorescent readout that separates viable, apoptotic, and necrotic cells in one workflow. It is especially useful for drug-response screening, organoid studies, and post-isolation quality control where membrane integrity and cell-state differences must be assessed quickly.

• A-1210477: Mapping MCL-1 Dependency

  2026-08-14

  A-1210477 is a selective MCL-1 inhibitor for dissecting how cancer cells evade mitochondrial apoptosis. This guide develops a dependency-centered assay strategy that separates target-specific apoptotic rescue from nonspecific cytotoxicity and clarifies the compound’s in vitro research value.

• PAK1, mRNA Decay, and Oxaliplatin in Colorectal Cancer

  2026-08-13

  A recent Genes & Diseases study identifies PAK1 as a regulator of oncogenic mRNA stability in colorectal cancer, linking kinase activity to the persistence of several tumor-promoting factors. The work also reports strong synergy between the PAK1 inhibitor PF3758309 and Oxaliplatin, providing a mechanistic rationale for investigating PAK1-directed combination strategies in colorectal cancer models.

• Jasplakinolide: Designing Better Actin Assays

  2026-08-13

  Jasplakinolide is a membrane-permeable actin polymerization inducer that can reveal how filament stabilization reshapes cell behavior. This guide moves beyond product description to show how chemical-genetic logic, orthogonal readouts, and careful controls improve actin cytoskeleton research.

• DiscoveryProbe Library Plus: From Hits to Mechanism

  2026-08-12

  DiscoveryProbe Bioactive Compound Library Plus connects broad chemical perturbation with thermal-shift and orthogonal validation strategies. This article explains how to convert library hits into defensible pathway and target hypotheses across apoptosis, cancer research, and bacterial signaling.

• Amorolfine Hydrochloride in Yeast Integrity Assays

  2026-08-12

  Use Amorolfine Hydrochloride as a mechanistic probe for connecting fungal cell membrane disruption with ploidy-dependent stress. This workflow pairs growth, membrane, and transcriptional readouts so researchers can distinguish direct integrity defects from slower proliferation or high-ploidy baseline effects.

• HDAC Inhibitors and NUT Carcinoma: Study Insights

  2026-08-11

  Shiota et al. developed a dCAS9-based GFP reporter screen that identified structurally diverse HDAC inhibitors as repressors of NUT transcriptional activity. The study connects HDAC inhibition with BRD4-NUT megadomain disruption, tumor-cell differentiation, and improved xenograft responses when combined with bromodomain inhibition.

• MCL-1 Inhibition: From Mechanism to Translation

  2026-08-11

  MCL-1 inhibitor A-1210477 offers a precise way to interrogate mitochondrial apoptosis, MCL-1 dependence, and combination sensitivity in cancer models. This thought-leadership perspective connects its BIM-disrupting mechanism with breast cancer evidence, assay strategy, competitive positioning, translational interpretation, and practical limitations including unfavorable pharmacokinetics.

• ABT-263 (Navitoclax) in Reliable Assays

  2026-08-10

  Learn how ABT-263 (Navitoclax), SKU A3007, can improve experimental consistency in apoptosis, viability, and cancer biology workflows. This scenario-based guide covers mechanism, solvent compatibility, protocol handling, data interpretation, and practical supplier selection.

• UK-5099: A Translational Lens on Immune Metabolism

  2026-08-09

  UK-5099 (PF-1005023) offers a mechanistic way to interrogate mitochondrial pyruvate transport across immune, cellular, and organismal models. This article translates product evidence and a standardized whole-blood stimulation protocol into a strategy for more rigorous immunometabolic assay design.

• Alosetron in Intestinal Signaling Research

  2026-08-08

  Use Alosetron as a controlled 5-HT3 receptor antagonist perturbation to separate serotonin-dependent effects from CDC42–YAP–EGF–mTOR signaling in intestinal models. This practical guide covers organoid setup, dose design, assay pairing, and troubleshooting without implying that Alosetron directly reproduces epithelial polarity loss.

16153 records 1/1077 page Next 12345 下5页 Last page